Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Non-Current Deffered Revenue (2021 - 2024)

Atara Biotherapeutics filings provide 4 years of Non-Current Deffered Revenue readings, the most recent being $470000.0 for Q3 2024.

  • On a quarterly basis, Non-Current Deffered Revenue fell 99.36% to $470000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $470000.0, a 99.36% decrease, with the full-year FY2023 number at $37.6 million, down 51.22% from a year prior.
  • Non-Current Deffered Revenue hit $470000.0 in Q3 2024 for Atara Biotherapeutics, down from $567000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $78.0 million in Q1 2023 to a low of $470000.0 in Q3 2024.
  • Median Non-Current Deffered Revenue over the past 4 years was $44.2 million (2022), compared with a mean of $44.2 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 74.62% in 2023 and later crashed 99.36% in 2024.
  • Atara Biotherapeutics' Non-Current Deffered Revenue stood at $55.7 million in 2021, then surged by 38.22% to $77.0 million in 2022, then tumbled by 51.22% to $37.6 million in 2023, then tumbled by 98.75% to $470000.0 in 2024.
  • The last three reported values for Non-Current Deffered Revenue were $470000.0 (Q3 2024), $567000.0 (Q2 2024), and $719000.0 (Q1 2024) per Business Quant data.